Sheryl Merkin, M.S., F.N.P., C.D.E., Sharon Movsas, M.S., R.D., C.D.E., and Joel Zonszein, M.D., C.D.E.

Dr. Zonszein is Professor of Clinical Medicine, Albert Einstein College of Medicine. All authors are staff members of the Clinical Diabetes Center of Montefiore Medical Center, New York.

Within the past 12 months, Dr. Zonszein has been on the Speakers Bureau of Merck, Sanofi Aventis, Takeda Pharmaceuticals, Eli Lilly & Co. and Novo Nordisk; Ms. Merkin has been on the Speakers Bureau of Sanofi Aventis and Novo Nordisk; Ms. Movsas reports no commercial conflicts of interest.

Release Date: 05/24/2006
Termination Date: 05/24/2009

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

• Describe the new classification of diabetes
• Discuss the pathogenesis of Type 1 diabetes
• Identify individuals with Type 1 diabetes using clinical and laboratory parameters.

 

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity